Document Detail


Elobixibat for the treatment of constipation.
MedLine Citation:
PMID:  23215781     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Elobixibat (formerly A3309) is a first-in-class ileal bile acid transporter (IBAT) inhibitor for treatment of chronic idiopathic constipation (CIC; syn functional constipation). CIC affects up to 25% of the general population; and up to a half are unsatisfied with current therapies. There is an unmet need for safe and effective drugs to treat CIC.
AREAS COVERED: The authors present: i) an overview of Phase II clinical trials of elobixibat in CIC, based on peer-reviewed literature and congress presentations and ii) an evaluation of the efficacy and mechanism of action of elobixibat in the treatment of CIC.
EXPERT OPINION: Elobixibat provides a novel approach to treat chronic constipation via IBAT inhibition with enhanced delivery of bile acids to the colon. Pharmacodynamic studies show that it accelerates colonic transit, increases stool frequency, loosens stool consistency and relieves constipation-related symptoms in CIC patients. These beneficial effects are maintained for a minimum of 8 consecutive weeks of treatment. With minimal absorption and low systemic bioavailability, elobixibat is generally well tolerated and may offer the added benefit of improving serum lipid profiles through bile acid depletion.
Authors:
Banny S Wong; Michael Camilleri
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-12-08
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  22     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-10     Completed Date:  2013-06-07     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  277-84     Citation Subset:  IM    
Affiliation:
College of Medicine, Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Carrier Proteins / antagonists & inhibitors*
Clinical Trials, Phase II as Topic
Constipation / drug therapy*,  metabolism,  physiopathology
Dipeptides / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Gastrointestinal Transit / drug effects*
Humans
Membrane Glycoproteins / antagonists & inhibitors*
Molecular Structure
Thiazepines / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Carrier Proteins; 0/Dipeptides; 0/Membrane Glycoproteins; 0/Thiazepines; 0/bile acid binding proteins; 0/elobixibat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ventral Surgical Approach to the Lumbosacral Joint in the Dog.
Next Document:  Influenza Virus Subpopulations: Exchange of Lethal H5N1 Virus NS for H1N1 Virus NS Triggers De Novo ...